| abstract | 第6-7页 |
| 摘要 | 第8-13页 |
| Chapter 1. Introduction | 第13-30页 |
| 1.1 Pharmacology and role traditional Chinese medicine (TCM) | 第13-19页 |
| 1.2 Systems pharmacology and traditional Chinese medicine (TCM) analysis stage | 第19-20页 |
| 1.3 Pharmacological study on the composition of Guanxin Shutong Capsule | 第20-22页 |
| 1.4 Discovery of the drug through the traditional Chinese medicine (TCM) | 第22-23页 |
| 1.5 Development of drug-related communication and interaction of drug target | 第23页 |
| 1.6 Drug design based on the drug target association | 第23-24页 |
| 1.7 The complication of pharmacological medicine | 第24页 |
| 1.8 Lack of unified system pharmacology for drug discovery | 第24-25页 |
| 1.9 Individuality trend of pharmacology | 第25-26页 |
| 1.10 Target proteins of guanxin shutong capsule formula | 第26-30页 |
| 1.10.1 Network construction and analysis | 第26-27页 |
| 1.10.2 Drug Likeness | 第27页 |
| 1.10.3 Oral Bioavailability prediction | 第27-28页 |
| 1.10.4 Computational interpretation methods | 第28-29页 |
| 1.10.5 The approach system pharmacology in drug safety | 第29-30页 |
| Chapter 2 The systemic pharmacological investigation level in the mechanisms of traditional Chinese medicine (TCM) through the Guanxin Shutong Capsule formula for the treatment of CHD and angina pectoris | 第30-57页 |
| 2.1 Introduction | 第30-31页 |
| 2.2 Material and methods | 第31-32页 |
| 2.3 Target identification | 第32页 |
| 2.4 Network construction | 第32页 |
| 2.5 Results | 第32-52页 |
| 2.5.1 Oral bioavailability prediction | 第33-34页 |
| 2.5.2 Pre DL | 第34页 |
| 2.5.3 Drug targeting and analysis | 第34页 |
| 2.5.4 Target pathway network constructions and analysis | 第34-35页 |
| 2.5.5 Choerospondiatis Fructus | 第35-36页 |
| 2.5.6 Caryophylli flos | 第36-37页 |
| 2.5.7 Borneolum Syntheticum | 第37-38页 |
| 2.5.8 Concretio silicea Bambusae | 第38-39页 |
| 2.5.9 Radix Salviae | 第39-52页 |
| 2.6 Compound target- network | 第52-57页 |
| 2.6.1 Target-disease network | 第53-54页 |
| 2.6.2 Gene ontology enrichment | 第54-55页 |
| 2.6.3 Compound target-pathway network disease | 第55-57页 |
| Chapter 3 The pharmacological uses of ginkgo biloba leave extracts for CHD and angina pectoris | 第57-70页 |
| 3.1 Introduction | 第57-60页 |
| 3.2 Chemical Constituents of Ginkgo Biloba Leaves | 第60-61页 |
| 3.3 Flavonoids | 第61-65页 |
| 3.3.1 CHD and angina pectoris | 第62-63页 |
| 3.3.2 Coronary heart disease and angina pectoris | 第63页 |
| 3.3.3 Arrhythmia | 第63页 |
| 3.3.4 Diabetic cardiomyopathy | 第63-64页 |
| 3.3.5 Dementia | 第64页 |
| 3.3.6 Cerebral infarction | 第64页 |
| 3.3.7 The anti-inflammatory response | 第64-65页 |
| 3.3.8 Regulation of blood lipids | 第65页 |
| 3.4 Advances in research on apoptosis of two myocardial ischemia - reperfusion injury cells | 第65-70页 |
| 3.4.1 Inflammatory cell response | 第66-67页 |
| 3.4.2 Cardiac cell energy metabolism disorder | 第67-68页 |
| 3.4.3 Medicinal and Pharmacological applications of Ginkgo biloba | 第68-70页 |
| Chapter 4 Traditional Chinese medicine (TCM) ginseng (Panax quinquennium L.) effects on anti-coronary heart disease and angina pectoris through the systematic pharmacology | 第70-81页 |
| 4.1 Introduction | 第70-71页 |
| 4.2 Traditional Chinese medicine (TCM) as an alternative therapy | 第71-72页 |
| 4.3 Treatment methods for CHD and angina pectoris | 第72页 |
| 4.4 Ginseng for prevention and treatment of CHD and angina pectoris | 第72-74页 |
| 4.5 Bioactive compounds of ginseng used for the treatment of CHD and angina pectoris | 第74-81页 |
| 4.5.1 Targets of ginseng | 第75-76页 |
| 4.5.2 System pharmacology of ginsenoside and ginseng | 第76-77页 |
| 4.5.3 Network construction | 第77-78页 |
| 4.5.4 Bioavailability of ginsenosides | 第78页 |
| 4.5.5 Other active components | 第78-79页 |
| 4.5.6 Ginseng is a novel herbal medicine for treatment of CHD and angina pectoris | 第79-81页 |
| Chapter 5 Discussion | 第81-87页 |
| 5.1 Conclusion | 第83-85页 |
| 5.2 Acknowledgement | 第85-87页 |
| REFERENCS | 第87-110页 |
| Curriculum Vitae | 第110-115页 |
